Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.2283
- Book/Share 15.6573
- PB 1.5854
- Debt/Equity 0.6967
- CurrentRatio 1.1584
- ROIC 0.1119
- MktCap 140632079250.0
- FreeCF/Share 2.1879
- PFCF 11.3066
- PE 13.1076
- Debt/Assets 0.2998
- DivYield 0.0691
- ROE 0.1194
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Buy Pfizer Stock At $24?
Published: August 05, 2025 by: Forbes
Sentiment: Positive
Pfizer (NYSE: PFE) has recently reported impressive second-quarter results, with both revenue and earnings exceeding analyst expectations. The company disclosed adjusted earnings of $0.78 per share on $14.65 billion in revenue, surpassing consensus estimates of $0.58 per share and $13.56 billion.
Read More
Pfizer raises profit forecast after Q2 earnings beat estimates
Published: August 05, 2025 by: Proactive Investors
Sentiment: Positive
Pfizer Inc (NYSE:PFE, ETR:PFE) raised its full-year profit outlook on Tuesday after posting better-than-expected second-quarter earnings, driven by strong sales of key drugs including Comirnaty and Paxlovid. The drugmaker reported adjusted earnings of $0.78 per share, beating analysts' average estimate of $0.58, according to LSEG data.
Read More
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Read More
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (August 2025)
Published: August 04, 2025 by: 24/7 Wall Street
Sentiment: Negative
Shares of Pfizer ( NYSE: PFE ) lost 6.50% over the past month, bringing the stock's year-to-date loss to 11.31%.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Pfizer: Earnings Meet Pressure (Rating Upgrade)
Published: August 04, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major concern for future growth. Valuation appears attractive with ratios below sector medians and Wall Street seeing significant upside, yet EPS stagnation tempers enthusiasm. Despite potential for another earnings beat, a miss could trigger a selloff, while the 7.3% dividend yield offers defensive appeal amid market uncertainty.
Read More
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.
Read More
Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Pfizer (PFE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Read More
2 Dividend Stocks Yielding Over 7% to Buy
Published: July 29, 2025 by: 24/7 Wall Street
Sentiment: Positive
PFE and CAG are two standout 7%-yielders that have relatively safe payouts. Headwinds facing both firms are tremendous, but there's already so much negativity priced in at these depths.
Read More
Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Pfizer's Comeback Is Underway
Published: July 25, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer's $7.7B cost-savings plan is boosting margins and EPS, offsetting COVID revenue declines and patent cliff concerns. Core business is growing 12% ex-COVID, with strength in oncology, vaccines, and internal medicine, plus a robust R&D pipeline. Major patent expirations threaten $15B+ in annual revenue by 2028, but Pfizer is aggressively pursuing pipeline and acquisition strategies.
Read More
16 Ideal 'Safer' Dividend Dogs To Buy From 70 July Graham Value All-Stars (GVAS)
Published: July 25, 2025 by: Seeking Alpha
Sentiment: Positive
Graham All Star Value (GASV) strategy identifies top dividend 'dogs' offering high yield and fair pricing, using YCharts' large cap value and Ben Graham screens. Analyst projections suggest the top ten GASV stocks could deliver average net gains of 27.55% by July 2026, with moderate risk. Sixteen of the twenty-one lowest-priced, 'safer' GASV dividend stocks are currently buyable, with dividends exceeding share price for ideal picks.
Read More
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
I Am Buying 5 Blue-Chip Dividend Stocks That Have Been Crushed in 2025
Published: July 24, 2025 by: 24/7 Wall Street
Sentiment: Positive
Blue-chip stocks are shares of large, well-established, financially stable companies with a consistent and reliable performance history.
Read More
5 Stocks Yielding 6% and More You Can Buy Now and Forget About Forever
Published: July 24, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.
Read More
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
Read More
Pfizer Nears Major Bottom: A Turning Point for Investors?
Published: July 23, 2025 by: FXEmpire
Sentiment: Positive
Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% in its stock price.
Read More
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that end up listed, we take a look at some of those that rank on the higher yield end for an initial look.
Read More
3 Ultra-Safe Dividend Stocks That Yield Over 5%
Published: July 17, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points These dividend stocks yield 5% or more.
Read More
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Published: July 17, 2025 by: CNBC
Sentiment: Neutral
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.
Read More
Dividend Harvesting Portfolio Week 228: $22,800 Allocated, $2,399.27 In Projected Dividends
Published: July 17, 2025 by: Seeking Alpha
Sentiment: Positive
The Dividend Harvesting Portfolio is thriving, generating strong recurring income and capital appreciation, with forward dividend income nearing $2,400 and a yield over 8%. My disciplined weekly allocation and diversified approach—spanning 102 positions—have mitigated downside risk and steadily grown income, even during market uncertainty. Recent additions to Bristol Myers Squibb, BP, and BSTZ reflect my focus on undervalued, high-yield opportunities positioned for growth amid potential Fed rate cuts.
Read More
I Sold Pfizer at a 13% Loss – Here's Why I'm Choosing Stability Over Risk
Published: July 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral
A Reddit poster took a big loss on Pfizer. They needed to dump some shares because they occupied a huge chunk of their portfolio.
Read More
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
Published: July 17, 2025 by: Reuters
Sentiment: Positive
US drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program.
Read More
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
Published: July 17, 2025 by: WSJ
Sentiment: Positive
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Read More
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Negative
PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
Read More
“Nobody Ever Went Broke Taking a Profit” – Grab The Highest-Yielding S&P 500 Stocks Right Now
Published: July 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who want to keep their money are in bonds.
Read More
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000